APLLTD - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.8
✅ Positive
APLLTD is currently exhibiting strong momentum with a significant quarter-over-quarter profit increase of 249%, indicating robust financial performance. The RSI at 46.4 suggests the stock isn't overbought, and the MACD value of 3.88 further supports this positive trend alongside increased volume compared to the weekly average.
⚠️ Limitation
Despite the strong recent earnings growth, the stock’s P/E ratio is relatively high (22.5) compared to the industry average (33.5), suggesting potential overvaluation and future price corrections are possible given current market conditions. The decrease in FII and DII holdings could indicate a lack of confidence from institutional investors.
📉 Company Negative News
None found
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is generally considered stable, with Alembic Pharmaceuticals benefiting from securing USFDA approval for a key product (Prucalopride Tablets). The industry continues to experience growth driven by increasing healthcare spending and innovation.
🧾 Conclusion
A potential entry point could be at 805 ₹, utilizing the current price as a base. An initial profit-taking target would be set at 820 ₹, representing an upside of 2.5%. As a stop-loss level, consider placing it at 790 ₹ to mitigate downside risk given the relatively high P/E ratio and recent decrease in institutional holdings. Overall, this stock presents a moderate trading opportunity due to its momentum but warrants cautious monitoring.